209 related articles for article (PubMed ID: 19375893)
1. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.
Citrome L; Yang R; Glue P; Karayal ON
Schizophr Res; 2009 Jun; 111(1-3):39-45. PubMed ID: 19375893
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
3. Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder.
Citrome L; Reist C; Palmer L; Montejano LB; Lenhart G; Cuffel B; Harnett J; Sanders KN
Schizophr Res; 2009 Dec; 115(2-3):115-20. PubMed ID: 19864113
[TBL] [Abstract][Full Text] [Related]
4. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder.
Potkin SG; Ogasa M; Cucchiaro J; Loebel A
Schizophr Res; 2011 Nov; 132(2-3):101-7. PubMed ID: 21889878
[TBL] [Abstract][Full Text] [Related]
5. Effect of initial ziprasidone dose on length of therapy in schizophrenia.
Joyce AT; Harrison DJ; Loebel AD; Carter CT; Ollendorf DA
Schizophr Res; 2006 Apr; 83(2-3):285-92. PubMed ID: 16545543
[TBL] [Abstract][Full Text] [Related]
6. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
Daniel DG; Zimbroff DL; Potkin SG; Reeves KR; Harrigan EP; Lakshminarayanan M
Neuropsychopharmacology; 1999 May; 20(5):491-505. PubMed ID: 10192829
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study.
Díaz-Marsá M; Sánchez S; Rico-Villademoros F;
J Clin Psychiatry; 2009 Apr; 70(4):509-17. PubMed ID: 19358789
[TBL] [Abstract][Full Text] [Related]
9. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.
Keck P; Buffenstein A; Ferguson J; Feighner J; Jaffe W; Harrigan EP; Morrissey MR
Psychopharmacology (Berl); 1998 Nov; 140(2):173-84. PubMed ID: 9860108
[TBL] [Abstract][Full Text] [Related]
10. Effect of initial ziprasidone dose on treatment persistence in schizophrenia.
Mullins CD; Shaya FT; Zito JM; Obeidat N; Naradzay J; Harrison DJ
Schizophr Res; 2006 Apr; 83(2-3):277-84. PubMed ID: 16545945
[TBL] [Abstract][Full Text] [Related]
11. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
Gunasekara NS; Spencer CM; Keating GM
CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335
[TBL] [Abstract][Full Text] [Related]
13. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
14. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
[TBL] [Abstract][Full Text] [Related]
15. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
16. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study.
Brook S; Walden J; Benattia I; Siu CO; Romano SJ
Psychopharmacology (Berl); 2005 Apr; 178(4):514-23. PubMed ID: 15650846
[TBL] [Abstract][Full Text] [Related]
17. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
[TBL] [Abstract][Full Text] [Related]
18. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
19. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.
Keck PE; Reeves KR; Harrigan EP;
J Clin Psychopharmacol; 2001 Feb; 21(1):27-35. PubMed ID: 11199944
[TBL] [Abstract][Full Text] [Related]
20. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
Stahl SM; Malla A; Newcomer JW; Potkin SG; Weiden PJ; Harvey PD; Loebel A; Watsky E; Siu CO; Romano S
J Clin Psychopharmacol; 2010 Aug; 30(4):425-30. PubMed ID: 20571437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]